A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis [M16-813]

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2019
This article has no abstract
Epistemonikos ID: 0c92a6cd56a18eaa67bdd06755de2c2c35ff9c92
First added on: Apr 11, 2025